Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Purecodon (Hong Kong) Biopharma Ltd. manages a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The data shows 1 pending office action currently active. This action is assigned to YOUNG, BRIAN ELLIS, who is the busiest examiner for the company. Because there is 1 distinct examiner and 1 distinct art unit involved, the company's current prosecution is handled by a point of review.
This structure means the outcome of the portfolio depends on the interpretation of YOUNG, BRIAN ELLIS. This examiner handles the 1 pending case, which means there is no distribution of risk across other examiners. The 1 distinct art unit involved indicates the technical focus within the Biotechnology & Pharmaceuticals field. The alignment of 1 distinct examiner with the current workload ensures that all feedback originates from the same source.
The 1 pending office action is the focus for the company's intellectual property management. With 1 distinct examiner, the applicant can study the examiner's preferences. This 1 distinct art unit placement indicates the technology is categorized in a single technical area. The busiest examiner is the individual currently providing feedback on the company's innovations. The 1 pending case with the busiest examiner defines the current status of the company's patent pipeline.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOUNG, BRIAN ELLIS | 1 | 65.0% | +28.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17964598 | LEVENSHTEIN DISTANCE-BASED IRES SCREENING METHOD AND POLYNUCLEOTIDE SCREENED BASED ON SAME | YOUNG, BRIAN ELLIS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17964598 | LEVENSHTEIN DISTANCE-BASED IRES SCREENING METHOD AND POLYNUCLEOTIDE SCREENED BASED ON SAME | YOUNG, BRIAN ELLIS | — |
| Art Unit | Apps |
|---|---|
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17964598 | LEVENSHTEIN DISTANCE-BASED IRES SCREENING METHOD AND POLYNUCLEOTIDE SCREENED BASED ON SAME | YOUNG, BRIAN ELLIS | 1684 | §101§112 | Non-Final OA | — | Pending | Oct 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPurecodon (Hong Kong) Biopharma Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Brian Ellis Young has the most, with 1 of Purecodon (Hong Kong) Biopharma Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
